The 340B Program is now the second largest government-run pharmaceutical program, behind only Medicare, reaching over $50 billion annually. This growth has been driven by healthcare consolidations, the expansion of covered entities’ reach through child sites, and the proliferation of contract pharmacies, which are third-party pharmacies that covered entities use to dispense 340B priced drugs. Meena Datta and Beth Hardcastle expand on the issue, below.
Copyright 2024 Bloomberg Industry Group, Inc. (800-372-1033) Compliance Considerations for 340B Drug Pricing Program. Reproduced with permission.
